Gretchen Santos, NP, MSN, FNP-BC
University of California San Francisco Helen Diller Family Comprehensive Cancer CenterAuthored Items
November 2019 Vol 10, No 11
Activating mutations in PIK3CA (the gene encoding the p110α catalytic subunit of class I phosphatidylinositol 3-kinase [PI3K] [PI3Kα]) lead to increased activity of the PI3K pathway and play a role in endocrine treatment resistance in breast cancer.
Last modified: November 6, 2019